Xencor, Inc. (NASDAQ:XNCR) Short Interest Update

Xencor, Inc. (NASDAQ:XNCR) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 4,830,000 shares, a decline of 12.9% from the June 15th total of 5,544,900 shares. Based on an average daily trading volume, of 622,400 shares, the short-interest ratio is presently 7.8 days.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Raymond James cut their price objective on shares of Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research report on Friday, June 14th. Royal Bank of Canada decreased their target price on shares of Xencor from $32.00 to $31.00 and set an “outperform” rating on the stock in a research report on Friday, June 14th. BTIG Research lowered their price target on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, April 16th. Wedbush reissued an “outperform” rating and issued a $34.00 price objective (down previously from $36.00) on shares of Xencor in a research note on Thursday, June 13th. Finally, BMO Capital Markets lowered their target price on Xencor from $34.00 to $32.00 and set an “outperform” rating for the company in a research note on Friday, June 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Xencor has a consensus rating of “Moderate Buy” and a consensus target price of $35.38.

Xencor Stock Performance

Shares of XNCR stock opened at $19.71 on Friday. Xencor has a 1 year low of $16.49 and a 1 year high of $26.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 7.08. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -9.00 and a beta of 0.69. The stock’s 50-day moving average is $21.34 and its two-hundred day moving average is $21.35.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.28). The firm had revenue of $12.80 million for the quarter, compared to analysts’ expectations of $23.07 million. Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. The company’s quarterly revenue was down 32.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.02) EPS. Analysts predict that Xencor will post -3.5 earnings per share for the current year.

Insider Buying and Selling

In related news, VP John R. Desjarlais sold 36,329 shares of the company’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $665,547.28. Following the completion of the sale, the vice president now owns 192,319 shares of the company’s stock, valued at approximately $3,523,284.08. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.23% of the stock is currently owned by insiders.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently bought and sold shares of XNCR. Parallel Advisors LLC increased its position in Xencor by 303.9% during the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,015 shares during the period. CWM LLC boosted its stake in shares of Xencor by 498.7% during the fourth quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 1,147 shares during the last quarter. Signaturefd LLC lifted its holdings in Xencor by 367.7% in the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,151 shares in the last quarter. GAMMA Investing LLC grew its stake in Xencor by 153.7% in the 1st quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 1,316 shares during the period. Finally, Allworth Financial LP grew its position in shares of Xencor by 29,487.5% in the fourth quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 2,359 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.